What’s the current market cap for Upstream Bio, Inc. stock?

Upstream Bio, Inc. (UPB) has a market cap of $322m as of June 17, 2026.

What is the P/E ratio for Upstream Bio, Inc. stock?

The price to earnings (P/E) ratio for Upstream Bio, Inc. (UPB) stock is 0 as of June 17, 2026.

Does Upstream Bio, Inc. stock pay dividends?

No, Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Upstream Bio, Inc. dividend payment date?

Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders.

What is the beta indicator for Upstream Bio, Inc.?

Upstream Bio, Inc. (UPB) does not currently have a Beta indicator.

Buy Upstream Bio, Inc. stock | $UPB Share Price

13:30

15:10

16:45

18:25

20:00

About Upstream Bio, Inc.

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

Ticker

$UPB

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Waltham, United States

Website

upstreambio.com

UPB Metrics

BasicAdvanced

$322m

-$2.90

Bulls say / Bears say

Upstream Bio reported positive top-line results from its Phase 2 VALIANT trial in severe asthma, demonstrating a 56% reduction in annualized asthma exacerbation rate, clinically meaningful improvements in lung function and a favorable safety profile. (Nasdaq)

As of December 31, 2025, the company held $341.5 million in cash and equivalents, providing sufficient runway through 2027 to advance its clinical programs with no immediate need for new financing. (Nasdaq)

Upstream Bio has a clear Phase 3 development strategy for verekitug in severe asthma and CRSwNP, planning to begin registrational studies in Q1 2027 following regulatory discussions, utilizing its strong Phase 2 results. (Nasdaq)

Upstream Bio’s stock fell 23% after investors reacted to perceived mixed Phase 2 VALIANT severe asthma data, highlighting market skepticism over the consistency and commercial potential of the results.

Research and development and general & administrative expenses rose year-over-year to $36.6 million and $8.1 million, respectively, resulting in a net loss of $40.6 million in Q1 2026 (compared to $27.3 million in Q1 2025) and increasing the company’s cash burn.

Verekitug is Upstream Bio’s only clinical-stage asset and the company has no products approved for commercial sale, leaving it exposed to binary risk if any trial results are unfavorable.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $UPB

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Verekitug is Upstream Bio’s only clinical-stage asset and the company has no products approved for commercial sale, leaving it exposed to binary risk if any trial results are unfavorable.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.